Discover our other sites:

You might be looking for...

THIS ARTICLE/PRESS RELEASE IS PAID FOR AND PRESENTED BY University of Oslo - read more

“The study helps to explain why some individuals are more susceptible to both cannabis use and certain psychiatric disorders”, says Nadine Parker, postdoctoral fellow at NORMENT.

(Photo: Colourbox)

The same genes are related to both cannabis use and serious mental disorders

A new study indicates that some individuals are more prone to both using cannabis and developing mental disorders, such as schizophrenia and bipolar disorder, than others.

Julie Nybakk Kvaal COMMUNICATIONS ADVISER

Presented by: University of Oslo

Published 4 July 2023 - 04:30

The relationship between cannabis use and psychiatric disorders has been widely debated.

Cannabis is a psychoactive and addictive drug which sometimes produces psychosis-like symptoms.

Psychiatric disorders such as schizophrenia and bipolar disorder are characterised by a severely disturbed perception of reality or a state of confusion.

Weiqiu Cheng, first author of the new study.

In a new study published in Lancet Psychiatry, researchers have shown that there are shared genetic factors underlying our susceptibility to both cannabis use and some psychiatric disorders.

“These findings may indicate that a subgroup of the population is at high risk for both cannabis use and certain psychiatric disorders, based on their genetics,” Weiqiu Cheng says.

She was first author of the study together with Nadine Parker. At the time of the study, they were both researchers at the Norwegian Center for Mental Disorders Research (NORMENT), a Centre of Excellence at the University of Oslo.

Our genetics play an important role

Individuals who use cannabis have a threefold risk of developing psychosis. Lifelong use of cannabis may also lead to the development of bipolar disorder.

“We know that genetic factors affect an individual's likelihood of using cannabis. We also know that genetic factors play an important role in determining an individual's susceptibility to developing psychiatric disorders,” Cheng says.

Genetic variants are differences in the DNA code between different individuals. When we talk about genetic variants associated with, for example, a particular psychiatric disorder like schizophrenia, it indicates that this variant may increase or decrease a person’s risk of developing that particular disorder.

“Previous research has shown that some of the genetic variants associated with cannabis use are also linked to psychiatric disorders,” Cheng says.

In other words, there is a genetic link between the use of cannabis and some psychiatric disorders. The researchers at NORMENT wanted to explore this genetic link even further with this study.

Explains why some are more susceptible than others

“The study helps to explain why some individuals are more susceptible to both cannabis use and certain psychiatric disorders,” Nadine Parker, a postdoctoral fellow at NORMENT, says.

Because not only is there a link between the genetic variants. It is actually the same genetic variants that cause a person’s susceptibility to both using cannabis and developing psychiatric disorders, such as schizophrenia and bipolar disorder.

Nadine Parker, postdoctoral fellow at NORMENT.

“These findings are important as they show that the complex links between cannabis use and these disorders may not only be caused by cannabis use itself, but could also be driven by shared genetic susceptibility,” Parker explains.

Preventive measures are needed

“We can use the information from the study to develop preventive measures aimed at people at high risk. This could, for example, be to reduce cannabis use among people with a high genetic risk of schizophrenia and bipolar disorder,” Cheng says.

Information about shared genetic variants can also contribute to the development of more targeted treatment efforts.

“Our improved knowledge about genetic overlap could be used to stratify patients for more specialised treatment plans,” Parker says.

Some genetic variants have opposing effects on cannabis use and psychosis

The results of the study showed that the majority of the shared gene variants increase the risk of both cannabis use and the development of either schizophrenia or bipolar disorder.

However, the researchers at NORMENT also found some genetic variants with the opposite effect on cannabis use and mental disorders.

“We also found gene variants that increase the risk of cannabis use, while also decreasing the risk of the two psychiatric disorders. This finding suggests a complex relationship,” Cheng says.

Could cannabis be a potential treatment for psychosis?

Cannabis is used medicinally for relief pain and as an antidepressant in some regions of the world. One component of cannabis is also being considered as a potential treatment for psychosis.

Among patients with disorders linked to psychosis, such as schizophrenia and bipolar disorder, the rate of cannabis use is higher than in the general population.

Shared genetic variants with opposing effects may suggest the presence of biological mechanisms that could support the beneficial effects of cannabis, the researchers point out.

Advanced statistical methods were used in the study

To explore the genetic association between the psychotic disorders and the use of cannabis, the researchers from NORMENT used advanced statistical modelling.

“We leveraged the latest genetic evidence for cannabis use, schizophrenia, and bipolar disorder in analyses using state of the art methods that assess genetic overlap, causality, and prediction,” Parker says.

The analysis was based on results of previously conducted genome-wide association studies on schizophrenia, bipolar disorder, cannabis use disorder, and lifetime cannabis use.

Combined, these studies were comprised of over 1 million participants. Genetic information from these previous studies was used to conduct the current analyses.

Reference:

Cheng et al. 'The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study', The Lancet Psychiatry, vol. 10, 2023. DOI: 10.1016/S2215-0366(23)00143-8 (Summary)